STOCK TITAN

Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags
conferences

Annovis Bio announced its President and CEO, Maria Maccecchini, Ph.D., will present at the National Institute on Aging (NIA) workshop on Dementia with Lewy Bodies. The workshop, titled 'Dementia with Lewy Bodies: Filling the Gaps in Translational and Clinical Research,' is jointly sponsored by NIA and the National Institute of Neurological Disorders and Stroke (NINDS). The event will take place on November 12-13, 2024, and will be available online for registered attendees.

Dr. Maccecchini's presentation, 'One Drug, Dual Effect: Buntanetap Improves Cognitive and Motor Functions, Benefiting Alzheimer's and Parkinson's Patients. A Potential Path for Lewy Body Dementia?' is scheduled for November 13 at 2:20-2:35 PM ET.

Annovis Bio ha annunciato che il suo Presidente e CEO, Maria Maccecchini, Ph.D., parteciperà al workshop del National Institute on Aging (NIA) sulla demenza con corpi di Lewy. Il workshop, intitolato 'Demenza con corpi di Lewy: colmare le lacune nella ricerca traslazionale e clinica,' è sponsorizzato congiuntamente dal NIA e dal National Institute of Neurological Disorders and Stroke (NINDS). L'evento si svolgerà dal 12 al 13 novembre 2024 e sarà disponibile online per i partecipanti registrati.

La presentazione della Dott.ssa Maccecchini, 'Un farmaco, doppio effetto: Buntanetap migliora le funzioni cognitive e motorie, beneficiando i pazienti con Alzheimer e Parkinson. Una potenziale strada per la demenza da corpi di Lewy?' è programmata per il 13 novembre dalle 14:20 alle 14:35 ET.

Annovis Bio anunció que su Presidente y CEO, Maria Maccecchini, Ph.D., presentará en el taller del National Institute on Aging (NIA) sobre la demencia con cuerpos de Lewy. El taller, titulado 'Demencia con cuerpos de Lewy: llenando los vacíos en la investigación traslacional y clínica,' es coauspiciado por el NIA y el National Institute of Neurological Disorders and Stroke (NINDS). El evento se llevará a cabo del 12 al 13 de noviembre de 2024 y estará disponible en línea para los asistentes registrados.

La presentación de la Dra. Maccecchini, 'Un fármaco, efecto dual: Buntanetap mejora las funciones cognitivas y motoras, beneficiando a los pacientes de Alzheimer y Parkinson. ¿Un posible camino para la demencia por cuerpos de Lewy?' está programada para el 13 de noviembre de 14:20 a 14:35 ET.

Annovis Bio는 CEO인 Maria Maccecchini 박사가 국립노화연구소(NIA)의 레비 소체 치매 워크숍에서 발표할 것이라고 발표했습니다. '레비 소체 치매: 전이 및 임상 연구의 격차 메우기'라는 제목의 워크숍은 NIA와 신경장애 및 뇌졸중 Quốc립연구소(NINDS) 공동 후원으로 진행됩니다. 이 행사는 2024년 11월 12일부터 13일까지 진행되며 사전 등록한 참석자에게 온라인으로 제공됩니다.

Maccecchini 박사의 발표 '하나의 약물, 두 가지 효과: Buntanetap이 인지 및 운동 기능을 개선하고 알츠하이머 및 파킨슨 병 환자에게 혜택을 줍니다. 레비 소체 치매를 위한 잠재적 경로?'는 11월 13일 오후 2:20부터 2:35 ET까지 예정되어 있습니다.

Annovis Bio a annoncé que sa Présidente et PDG, Maria Maccecchini, Ph.D., présentera lors de l'atelier du National Institute on Aging (NIA) sur la démence à corps de Lewy. L'atelier, intitulé 'Démence à corps de Lewy : combler les lacunes de la recherche translationnelle et clinique,' est co-parrainé par le NIA et le National Institute of Neurological Disorders and Stroke (NINDS). L'événement se déroulera du 12 au 13 novembre 2024 et sera disponible en ligne pour les participants enregistrés.

La présentation de Dr. Maccecchini, 'Un médicament, effet double : Buntanetap améliore les fonctions cognitives et motrices, bénéficiant aux patients atteints d'Alzheimer et de Parkinson. Un chemin potentiel pour la démence à corps de Lewy ?' est prévue pour le 13 novembre de 14h20 à 14h35 ET.

Annovis Bio gab bekannt, dass die Präsidentin und CEO, Maria Maccecchini, Ph.D., auf dem Workshop des National Institute on Aging (NIA) zur Lewy-Körper-Demenz präsentieren wird. Der Workshop mit dem Titel 'Lewy-Körper-Demenz: Lücken in der translationalen und klinischen Forschung schließen' wird gemeinsam von NIA und dem National Institute of Neurological Disorders and Stroke (NINDS) ausgerichtet. Die Veranstaltung findet am 12. und 13. November 2024 statt und wird für registrierte Teilnehmer online verfügbar sein.

Dr. Maccecchini's Präsentation, 'Ein Medikament, doppelte Wirkung: Buntanetap verbessert kognitive und motorische Funktionen und kommt Alzheimer- und Parkinson-Patienten zugute. Ein möglicher Weg zur Lewy-Körper-Demenz?' ist für den 13. November von 14:20 bis 14:35 Uhr ET geplant.

Positive
  • None.
Negative
  • None.

MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that its President and CEO, Maria Maccecchini, Ph.D., has been invited to speak at the National Institute on Aging (NIA) workshop, “Dementia with Lewy Bodies: Filling the Gaps in Translational and Clinical Research.” This prestigious workshop, sponsored by the NIA and the National Institute of Neurological Disorders and Stroke (NINDS), will be held on November 12-13, 2024, and accessible online for registered attendees.

Presentation Details:

  • Title: One Drug, Dual Effect: Buntanetap Improves Cognitive and Motor Functions, Benefiting Alzheimer's and Parkinson's Patients. A Potential Path for Lewy Body Dementia?
  • Date and Time: Wednesday, November 13, 2:20–2:35 PM ET
  • Registration Link: Register for the Workshop

About the DLB Workshop: This workshop, sponsored by NIA and NINDS, is a collaborative event bringing together leading researchers and scientists from various disciplines to address critical gaps in DLB research. The event aligns with the goals of the National Plan to address AD and related dementias by encouraging innovative approaches and fostering dialogue on advancements in research and treatment options.

About Annovis Bio

Headquartered in Malvern, Pennsylvania, Annovis Bio is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedInYouTube, and X.

Investor Alerts

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at https://www.annovisbio.com/email-alerts. Additionally, we invite you to explore our updated investor website, which provides comprehensive access to company news, financial reports, and other key information.

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, the Company's plans related to clinical trials. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, but are not limited to, those related to patient enrollment, the effectiveness of Buntanetap, and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety, and tolerability of Buntanetap. Additional risk factors are detailed in the Company's periodic filings with the SEC, including those listed in the "Risk Factors" section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements in this press release are based on information available to the Company as of the date of this release. The Company expressly disclaims any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:
Scott McGowan
InvestorBrandNetwork (IBN)
Phone: 310.299.1717
www.annovisbio.com/investors-relations
IR@annovisbio.com


FAQ

What is the topic of Annovis Bio's presentation at the NIA workshop in November 2024?

Annovis Bio (ANVS) will present on Buntanetap's dual effect in improving cognitive and motor functions for Alzheimer's and Parkinson's patients, exploring its potential for Lewy Body Dementia.

When and where will Annovis Bio (ANVS) present at the NIA workshop?

The presentation will take place on Wednesday, November 13, 2024, from 2:20-2:35 PM ET during the online NIA workshop on Dementia with Lewy Bodies.

Which organizations are sponsoring the Dementia with Lewy Bodies workshop featuring Annovis Bio (ANVS)?

The workshop is jointly sponsored by the National Institute on Aging (NIA) and the National Institute of Neurological Disorders and Stroke (NINDS).

What neurodegenerative diseases is Annovis Bio (ANVS) developing treatments for?

Annovis Bio is developing treatments for neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD).

Annovis Bio, Inc.

NYSE:ANVS

ANVS Rankings

ANVS Latest News

ANVS Stock Data

93.61M
10.98M
20.4%
8.77%
10.72%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
MALVERN